GSK to Acquire 35Pharma for $950M, Bolstering Cardiopulmonary Pipeline with HS235
Summary
GSK announced the acquisition of 35Pharma Inc. for $950 million, adding HS235, a promising clinical-stage asset for cardiopulmonary diseases, to its pipeline.
Key Events
-
Acquisition of 35Pharma Inc.
GSK will acquire 100% of 35Pharma Inc., a clinical-stage biopharmaceutical company, for $950 million in cash.
-
Pipeline Expansion with HS235
The acquisition includes HS235, a potentially best-in-class activin signalling inhibitor that has completed Phase I trials and is set to begin studies for pulmonary arterial hypertension (PAH) and PH due to heart failure with preserved ejection fraction (PH-HFpEF).
-
Strategic Fit and Market Potential
HS235 targets a global market for PH therapies forecast to reach $18 billion by 2032 and offers a differentiated profile with reduced bleeding risk and metabolic benefits, bolstering GSK's Respiratory, Immunology and Inflammation portfolio.
Analysis
GSK's acquisition of 35Pharma Inc. for $950 million significantly expands its Respiratory, Immunology and Inflammation (RI&I) portfolio. The key asset, HS235, is a clinical-stage activin signalling inhibitor for pulmonary hypertension (PH), a life-shortening disease with a large addressable market. HS235's differentiated profile, including reduced bleeding risk and potential metabolic benefits, positions it as a potentially best-in-class therapy. This strategic move enhances GSK's long-term growth prospects in a high-value therapeutic area.
At the time of this filing, GSK was trading at $59.73 on NYSE in the Life Sciences sector, with a market capitalization of approximately $119.7B. The 52-week trading range was $32.38 to $61.70. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.